Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsBjörnsson, Einar S
MetadataShow full item record
CitationHepatotoxicity of statins and other lipid-lowering agents. 2017, 37 (2):173-178 Liver Int.
AbstractStatins are generally well tolerated and adverse effects are relatively rare. Clinical trials are underpowered to detect uncommon adverse effects such as idiosyncratic drug-induced liver injury. This review is aimed at covering the current knowledge on the hepatotoxicity associated with statins and other lipid lowering drugs. Both atorvastatin and simvastatin have been associated with more than 50 case reports of liver injury and other statins have been implicated in this type of liver injury as well. Idiosyncratic liver injury due to statins has been reported to occur 1.9%-5.5% of patients in prospective series of drug-induced liver injury. Atorvastatin and simvastatin have been associated with positive rechallenge and some case reports have described liver injury following dose escalation of the implicated statin. Mortality from liver injury and/or liver transplantation has been documented in a few patients with statin induced liver injury although the vast majority of patients with liver injury have recovered after cessation of therapy.
DescriptionNeðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn View/Open To access publisher's full text version of this article click on the hyperlink at the bottom of the page
RightsArchived with thanks to Liver international : official journal of the International Association for the Study of the Liver
- Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing.
- Authors: Björnsson E, Jacobsen EI, Kalaitzakis E
- Issue date: 2012 Feb
- Acute liver failure following atorvastatin dose escalation: is there a threshold dose for idiosyncratic hepatotoxicity?
- Authors: Carrascosa MF, Salcines-Caviedes JR, Lucena MI, Andrade RJ
- Issue date: 2015 Mar
- [Rhabdomyolysis and severe hepatotoxicity due to a drug-drug interaction between ritonavir and simvastatin. Could we use the most cost-effective statin in all human immunodeficiency virus-infected patients?].
- Authors: Bastida C, Also MA, Pericas JM, Letang E, Tuset M, Miró JM
- Issue date: 2014 Nov
- Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study.
- Authors: Chang CH, Chang YC, Lee YC, Liu YC, Chuang LM, Lin JW
- Issue date: 2015 Jan
- Effect of statins on blood pressure: Analysis on adverse events released by FDA.
- Authors: You T, Liu XG, Hou XD, Wang XK, Xie HH, Ding F, Yi K, Zhang P, Xie XD
- Issue date: 2017